625 results on '"Frye, Stephen V."'
Search Results
2. Structural basis of paralog-specific KDM2A/B nucleosome recognition
3. Discovery of FERM domain protein–protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer’s disease
4. Discovery of hit compounds for methyl-lysine reader proteins from a target class DNA-encoded library
5. Reprogramming CBX8-PRC1 function with a positive allosteric modulator
6. MERTK Is a Potential Therapeutic Target in Ewing Sarcoma.
7. Development of [18F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease
8. Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors
9. UNC5293, a potent, orally available and highly MERTK-selective inhibitor
10. Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine
11. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
12. Efforts toward discovering inhibitors of the SYK SH2–FCER1γ interaction as potential Alzheimer’s disease chemical probes and therapeutics
13. Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma
14. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer
15. The promise and peril of chemical probes
16. Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7
17. A General TR-FRET Assay Platform for High-Throughput Screening and Characterizing Inhibitors of Methyl-Lysine Reader Proteins
18. Fused Tetrahydroquinolines Are Interfering with Your Assay
19. Discovery of a 53BP1 Small Molecule Antagonist Using a Focused DNA-Encoded Library Screen
20. SETDB1 Triple Tudor Domain Ligand, (R,R)-59, Promotes Methylation of Akt1 in Cells
21. Use of Protein Kinase–Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors
22. The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells
23. Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
24. Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer’s disease
25. Small-Molecule Modulation of Methyl-Lysine-Mediated Interactions
26. An autoinhibited state of 53BP1 revealed by chemical probes and protein engineering
27. Supplemental Figure Legends from TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma
28. Supplementary Figures from TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma
29. Data from TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma
30. Supplemental Materials and Methods from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
31. Data from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
32. Supplementary Figure 3 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo
33. Supplementary Figure 2 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo
34. Supplementary Figure 4 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo
35. Supplemental Figure 5 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
36. Supplementary Figure 1 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo
37. Data from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
38. Figure S4 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
39. Data from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo
40. Data from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
41. Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
42. Supplemental Figure 3 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
43. Supplemental Table 1 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
44. Supplemental Figure 4 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
45. Supplemental Figure 1 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
46. Supplementary Figure 5 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo
47. Supplemental Figure 1 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
48. Supplemental Figure 3 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
49. Table S1 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
50. Supplemental Figure 7 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.